2023 - Research.com Neuroscience in Australia Leader Award
2022 - Research.com Biology and Biochemistry in Australia Leader Award
2015 - Fellow of the Australian Academy of Health and Medical Science
The scientist’s investigation covers issues in Biochemistry, Alzheimer's disease, Amyloid precursor protein, Amyloid and P3 peptide. The Biochemistry study combines topics in areas such as Toxicity and Cell biology. His Alzheimer's disease study is concerned with Internal medicine in general.
His research integrates issues of Molecular biology and Neurodegeneration in his study of Amyloid precursor protein. Pathology covers Colin L. Masters research in Amyloid. He combines subjects such as Biochemistry of Alzheimer's disease, Clioquinol and Transgene with his study of P3 peptide.
His primary areas of investigation include Disease, Alzheimer's disease, Internal medicine, Biochemistry and Amyloid precursor protein. He interconnects Cognition and Immunology in the investigation of issues within Disease. His Alzheimer's disease study incorporates themes from Apolipoprotein E, Dementia, Neuroscience and Degenerative disease.
His biological study spans a wide range of topics, including Endocrinology and Oncology. Colin L. Masters studied Amyloid precursor protein and Amyloid that intersect with Genetically modified mouse. The study incorporates disciplines such as Biochemistry of Alzheimer's disease and Alpha secretase in addition to P3 peptide.
Colin L. Masters spends much of his time researching Disease, Internal medicine, Neuroscience, Pathology and Dementia. His Disease research incorporates elements of Cerebrospinal fluid, Microvesicles, Cell biology, Biomarker and Positron emission tomography. His Internal medicine study combines topics in areas such as Endocrinology and Oncology.
Amyloid, Clinical progression and Amyloid pet are among the areas of Pathology where Colin L. Masters concentrates his study. He has researched Dementia in several fields, including Alzheimer's disease, Gerontology and Neuropsychology. His Alzheimer's disease research is multidisciplinary, relying on both Magnetic resonance imaging, Hyperintensity and Apolipoprotein E.
Colin L. Masters mainly focuses on Disease, Alzheimer's disease, Internal medicine, Apolipoprotein E and Dementia. The various areas that Colin L. Masters examines in his Alzheimer's disease study include Computational biology, Biomarker, Neurology, Neuroscience and Receiver operating characteristic. His work deals with themes such as Endocrinology, Magnetic resonance imaging and Oncology, which intersect with Internal medicine.
Colin L. Masters has included themes like Pittsburgh compound B, Amyloid beta, Senile plaques and Pathology in his Positron emission tomography study. His Amyloid research is multidisciplinary, incorporating perspectives in Machine learning and Artificial intelligence. His Amyloid precursor protein study focuses on P3 peptide in particular.
This overview was generated by a machine learning system which analysed the scientist’s body of work. If you have any feedback, you can contact us here.
Imaging beta-amyloid burden in aging and dementia.
Christopher C Rowe;Steven Ng;Uwe Ackermann;Sylvia Gong.
High performance plasma amyloid-β biomarkers for Alzheimer’s disease
Akinori Nakamura;Naoki Kaneko;Victor L Villemagne;Takashi Kato.
The Amyloid Precursor Protein of Alzheimer's Disease in the Reduction of Copper(II) to Copper(I)
Gerd Multhaup;Andrea Schlicksupp;Lars Hesse;Dirk Beher.
Distinct sites of intracellular production for Alzheimer's disease A beta40/42 amyloid peptides.
Tobias Hartmann;Sophie C. Bieger;Babara Brühl;Pentti J. Tienari.
Nature Medicine (1997)
The Australian Imaging, Biomarkers and Lifestyle (AIBL) study of aging: Methodology and baseline characteristics of 1112 individuals recruited for a longitudinal study of Alzheimer's disease
Kathryn A Ellis;Ashley I Bush;David Darby;Daniela De Fazio.
International Psychogeriatrics (2009)
Safety, efficacy, and biomarker findings of PBT2 in targeting Aβ as a modifying therapy for Alzheimer's disease: a phase IIa, double-blind, randomised, placebo-controlled trial
Lars Lannfelt;Kaj Blennow;Henrik Zetterberg;Stellan Batsman.
Lancet Neurology (2008)
What the evolution of the amyloid protein precursor supergene family tells us about its function.
E.J Coulson;K Paliga;K Beyreuther;C.L Masters.
Neurochemistry International (2000)
Metalloenzyme-like Activity of Alzheimer's Disease β-Amyloid Cu-DEPENDENT CATALYTIC CONVERSION OF DOPAMINE, CHOLESTEROL, AND BIOLOGICAL REDUCING AGENTS TO NEUROTOXIC H2O2
Carlos Opazo;Xudong Huang;Robert A. Cherny;Robert D. Moir.
Journal of Biological Chemistry (2002)
Rapid Restoration of Cognition in Alzheimer's Transgenic Mice with 8-Hydroxy Quinoline Analogs Is Associated with Decreased Interstitial Aβ
Paul A. Adlard;Robert A. Cherny;Robert A. Cherny;David I. Finkelstein;David I. Finkelstein;Elisabeth Gautier.
Iron-Export Ferroxidase Activity of β-Amyloid Precursor Protein Is Inhibited by Zinc in Alzheimer's Disease
James A. Duce;Andrew Tsatsanis;Michael A. Cater;Simon A. James.
If you think any of the details on this page are incorrect, let us know.
We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below: